Clinical Trial Update: Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating CJM112 for inadequately controlled severe asthma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• CJM112

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Asthma | Phase 2 | Status: COMPLETED | Results posted: 2020-08-06